Rationale: Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare subtype of non-Hodgkin lymphoma, which is rarely associated with erythema nodosum (EN).
Introduction
Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a subtype of cutaneous T-cell lymphoma histologically characterized by large, highly atypical CD30+ T-cells. [1] The incidence of pcALCL among other types of peripheral T-cell NHL is 1.7%. Erythema nodosum (EN) is a panniculitis consisting of an infiltrate of lymphocytes and multinucleate giant cells within subcutaneous fat. [2] Previously, fewer than 10 cases have been reported about pcALCL arising from atopic dermatitis (AD) and burn scar. [3] [4] [5] [6] To our knowledge, there was no report of pcALCL arising from a long-standing EN.
Here we report the rare case of pcALCL occurring in a patient with over 20-year history of EN and achieved good clinical response with oral prednisone, cyclosporine, and thalidomide.
Case report
This study was approved by the ethics committee of the First Affiliated Hospital of Dalian Medical University, Dalian, China. Informed consent was obtained from the patient for publication of this report.
A 57-year-old woman was admitted to our hospital in May 2014 with complaints of a disseminated rash involving her abdomen, back, upper, and lower limbs which could regress without therapy spontaneously for over 20 years. The first skin biopsy was performed in another hospital in December 2011. Histopathological examination demonstrated that a dense lymphocytic infiltrate around deep plexus capillaries ( Fig. 1A and 1B) . The patient did not have any other symptoms, and no secondary diseases, such as rheumatologic diseases, tuberculosis, and tumor. She was diagnosed idiopathic EN and was given oral tripterygium glycosides daily for half a year, without improvement. With a gradually enlarged ulcerative lesion (7 cm Â 5 cm) in the right of lower limb in May 2014, the lesion biopsy was performed again in our hospital. It showed diffuse proliferation and invasion of largesized lymphoid cells with pleomorphic nuclei containing conspicuous nucleoli and relatively rich cytoplasm ( Fig. 1C and 1D ). Immunohistochemical panel showed that these lymphoid cells expressed CD30, CD3, CD4, Ki67, and were negative for CD8, CD20, ALK, EBER, CD56 and granzyme B. Complete blood count, metabolic panels, antinuclear antibodies, positron emission tomography/computed tomography scan (PET/CT), and bone marrow biopsy were unremarkable. b2-microglobulin was 3.84 mg/L and LDH was 364U/L in serum which was both slightly higher than normal. All tests did not show evidence of systemic involvement. Accordingly, a diagnosis of pcALCL with stage IA (T 1 N 0 M 0 B 0 ) was made, with <10% skin involvement. Considering her age, the size, and location of ulcerative lesion, she was treated with oral prednisone 30 mg daily, cyclosporine 200 mg daily and thalidomide 100 mg daily. After 1 month treatment, the ulcerative lesion was decreased in the size (4 cm Â 3 cm) and became smooth, achieved partial remission. She is still on treatment and is monitored closely for 4 years. She is generally in good condition. The erythemas nodules are smaller and without ulcers.
Discussion
There are a few reports regarding EN transforming into subcutaneous panniculitis lymphoma and Hodgkin lymphoma, however, EN transforming into pcALCL has not been reported. [7] To date, fewer than 10 cases with pcALCL occurring in AD and burn scar have been reported. [3] [4] [5] [6] In this case, pcALCL developed at the site of EN after 20 years. It seems advisable to perform careful and continuous follow-up of all cases with EN, with regular repetition of skin biopsies at appropriate intervals.
Biopsy of lesions from the patient expressed CD30 in the tumor cells, did not exhibit ALK. CD30 is a TNF receptor superfamily member, which is an activation antigen of lymphoid cells and express in a subset of lymphocytes with a Th2 phenotype. It has been reported that CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. [8] Stimulation of inflammation in the skin lesions and dysfunction of immune system for a long time might be related to clonal transformation, further studies are needed to clarify the pathogenesis. Because pcALCL is rare, prognostic variables have not been prospectively validated. Risk factors for worse prognosis may include involvement of the leg and more extensive disease based on a proposed tumor node metastasis staging system. Previous 5 cases arising from AD, 2 of them died earlier, 1 relapsed several times and only 1 was freed from disease after bone marrow transplantation. [3] [4] [5] It revealed that AD history may be another poor factor for pcALCL prognosis, however, we were unable to obtain any conclusive evidence to show the prognosis of pcALCL with EN history now. As in the case, the patient achieved good clinical response owing partly to the early stage and partly to the effective treatment. It has been demonstrated variety therapy, such as excision, external beam radiation, methotrexate, thalidomide, and chemotherapy are useful in treatment of pcALCL, but there is no standard treatment for this tumor. [1, 9, 10] Considering the size and wide distribution of erythema nodules presented, it is not suitable for radiotherapy and surgery resection. Chemotherapy may be useful for the patient, but it is easy to recurrence. Our promising result suggests that combination of prednisone, cyclosporine and thalidomide may be a useful method in the treatment of pcALCL. It is also necessary to closely monitor the patient because of the potential risk of dissemination, besides recurrence of the disease or even development of other malignancies. Recently, brentuximab vedotin was approved by FDA for relapsed or refractory Hodgkin's lymphoma and ALCL, with impressive response rates of 75% and 86%, respectively. Brentuximab vedotin is an antibody-drug conjugate that contains anti-CD30 Fab' domains linked to the antimitotic agent monomethyl auristatin E. [11] A 60-year-old man with a 6 cm pcALCL located on the right cheek, near the eye, received brentuximab vedotin therapy after failing 4 months of methotrexate. After 2 cycle's treatment, he had a complete response that was histologically confirmed. [12] This demonstrates that brentuximab vedotin may be an effective option for pcALCL in the future.
